Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.360
+0.230 (5.57%)
At close: Apr 14, 2025, 4:00 PM
4.278
-0.082 (-1.89%)
Pre-market: Apr 15, 2025, 7:00 AM EDT
Vanda Pharmaceuticals Employees
Vanda Pharmaceuticals had 368 employees as of December 31, 2024. The number of employees increased by 165 or 81.28% compared to the previous year.
Employees
368
Change (1Y)
165
Growth (1Y)
81.28%
Revenue / Employee
$540,141
Profits / Employee
-$51,359
Market Cap
254.26M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| HCA Healthcare | 316,000 |
| Thermo Fisher Scientific | 125,000 |
| Medtronic | 95,000 |
| AstraZeneca | 92,900 |
| Sanofi | 82,878 |
| Novartis AG | 75,883 |
| Becton, Dickinson and Company | 73,000 |
| GSK plc | 68,629 |
VNDA News
- 8 days ago - Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting - PRNewsWire
- 15 days ago - Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - PRNewsWire
- 7 weeks ago - Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis - PRNewsWire
- 3 months ago - Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review - PRNewsWire